Tharimmune, Inc. is a clinical-stage biotechnology company developing a portfolio of therapeutic candidates for inflammation and immunology. The company is headquartered in Bridgewater, New Jersey and currently employs 2 full-time employees. The company went IPO on 2022-01-12. The firm is engaged in developing therapeutic candidates for inflammatory and immunologic conditions with unmet need. The company has a transmucosal film product, TH104, is a Phase II ready clinical candidate and an oral biologic as well as two bispecific biologics in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. The company is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology targets including human epidermal growth factor receptor 2, human EGF receptor 3 and programmed cell death protein. The firm is developing antibodies, including bispecific antibodies, antibody drug conjugates, among others.
Follow-Up Questions
Who is the CEO of Tharimmune Inc?
Mr. Randy Milby is the Chairman of the Board of Tharimmune Inc, joining the firm since 2017.
What is the price performance of THAR stock?
The current price of THAR is $2.95, it has increased 2.82% in the last trading day.
What are the primary business themes or industries for Tharimmune Inc?
Tharimmune Inc belongs to Biotechnology industry and the sector is Health Care
What is Tharimmune Inc market cap?
Tharimmune Inc's current market cap is $20.0M
Is Tharimmune Inc a buy, sell, or hold?
According to wall street analysts, 3 analysts have made analyst ratings for Tharimmune Inc, including 2 strong buy, 4 buy, 1 hold, 0 sell, and 2 strong sell
